- Home
- BOLD
as 07-26-2024 4:00pm EST
Stocks
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
| Founded: | 2018 | Country: | Canada |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 79.4M | IPO Year: | 2024 |
| Target Price: | $23.00 | AVG Volume (30 days): | 109.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.40 - $15.24 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Boundless Bio Inc. Common Stock (BOLD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 296,875 | $4,750,000.00 | 1,884,787 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 15,625 | $250,000.00 | 295,844 | SEC Form 4 |
| ARCH Venture Fund IX, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 66,667 | $1,066,672.00 | 683,759 | SEC Form 4 |
| ARCH Venture Fund IX, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 133,333 | $2,133,328.00 | 1,181,766 | SEC Form 4 |
| Burow Kristina | BOLD | Director10% Owner | Apr 2 '24 | Buy | $16.00 | 66,667 | $1,066,672.00 | 683,759 | SEC Form 4 |
| Burow Kristina | BOLD | Director10% Owner | Apr 2 '24 | Buy | $16.00 | 133,333 | $2,133,328.00 | 1,181,766 | SEC Form 4 |
| CRANDELL KEITH | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 66,667 | $1,066,672.00 | 683,759 | SEC Form 4 |
| CRANDELL KEITH | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 133,333 | $2,133,328.00 | 1,181,766 | SEC Form 4 |
Latest Boundless Bio Inc. Common Stock News
BOLD Breaking Stock News: Dive into BOLD Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Business Wire
2 months ago
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Business Wire
3 months ago
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
Business Wire
3 months ago
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
Business Wire
4 months ago
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Compare BOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BOLD Boundless Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.